ERBB2 and hepatocellular carcinoma: Notably, the expression of PD-L1 was higher in the Afatinib monotherapy group and the combination of afatinib+Anti-PD1 group, highlighting the importance of targeting both ERBB2 and PD-1/PD-L1 pathways for HCC treatment.